A quicker, cheaper SARS virus detector -- one easily customizable for other targetsMay 29, 2009Members of a USC-led research team say they've made a big improvement in a new breed of electronic detectors for viruses and other biological materials - one that may be a valuable addition to the battle against epidemics. It consists of a piece of synthetic antibody attached to a nanowire that's attached to an electrical base, immersed in liquid. If the protein the antibody binds to is present in the liquid, it will bind to these antibodies, immediately creating a sharply measurable jump in current through the nanowire. The basic principle of nanotube and nanowire biosensors for protein detection was first demonstrated in 2001, but the new design by a team headed by Zhongwu Chou and Mark Thompson of the University of Southern California uses two new elements. First, it takes advantage of bioengineered synthetic antibodies, much, much smaller versions of the natural substances that are designed to bind with a specific protein and only that protein. Second, it uses indium oxide (In2O3) nanowires instead of silicon and other materials previously tried. Metal oxides, according to a new study published in ACSNano, do not, unlike silicon, develop "an insulating native oxide layer that can reduce sensitivity." The result, according to the paper, is a device that can detect its target molecules with a sensitivity as great as the best alternative modes, do so more rapidly and without use of chemical reagents. It is also potentially considerably cheaper than alternatives. "We believe," the authors write, "that nanowire bisensor devices functionalized with engineered proteins - can have important applications ranging from disease diagnosis to homeland security." Additionally, the system can be useful in basis research, in helping to establish certain important parameters for two-part biological systems like the antibody/target protein pair. The protein the prototype system detects is the SARS (severe acute respiratory syndrome) virus n-protein, which infected more than 8,000 people in 2002-2003, killing nearly 10 percent of them. Commercial systems using enzyme-linked immunosorbent assay (ELISA) now exist to test for SARS, but the new system has advantages in time, cost and portability. The first step was the creation, by Richard Roberts and Mark Thompson, chemists, and their team of the synthetic antibody, including both the active area, design to interact with the protein and, at the other end, a chemical "hook" that would bind it to nanowire at this point and only this point. "This - strategy allows every bound [detector molecule] to retain full activity, a clear advantage over antibodies, which [in earlier biosensor designs] are often bound to nanowire surface via amine containing residues randomly distributed over the antibody surface." The Zhou lab, which has specialized in nanowire and nanotube technology for years, performed the complex set of procedures to synthesize the wires, attaching In tests, the group performed if anything better than predictions, showing a standard and low level of activity when no SARS protein was present, leaping quickly to a higher level when the protein was introduced, in response patterns that varied consistently according to concentration of the SARS protein. Devices complete except for the detector molecule showed no response at all. The response was complete in less than ten minutes, compared to hours needed for results from ELISA tests - which are basically present/not present tests with relatively little quantitative elements. Next steps are to enable detection in more complex environment, such as Serum and whole blood, by integrating the nanobiosensor with micro systems such as microfluidics chips and micro filters. University of Southern California |
|||||||||||||||||||||
| Related SARS Virus Current Events and SARS Virus News Articles 2-pronged protein attack could be source of SARS virulence Ever since the previously unknown SARS virus emerged from southern China in 2003, University of Texas Medical Branch at Galveston virologists have focused on finding the source of the pathogen's virulence - its ability to cause disease. Protein from algae shows promise for stopping SARS A protein from algae may have what it takes to stop Severe Acute Respiratory Syndrome (SARS) infections, according to new research. Researchers recreate SARS virus, open door for potential defenses against future strains Researchers at the University of North Carolina at Chapel Hill and Vanderbilt University Medical Center have synthetically reconstructed the bat variant of the SARS coronavirus (CoV) that caused the SARS epidemic of 2003. Purdue researcher invents molecule that stops SARS A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease. Colds and flu cut by one-third in study of Canada's top cold fighter in vaccinated seniors A winter free from colds and flu? Not yet. But a new study offers new evidence that Canada's top cold and flu-fighting product provides significant help. An unexpected link between coronavirus replication and protein secretion in infected cells Coronavirus replication is critically linked to two factors within the early secretory pathway, according to new findings by a team of Dutch researchers that are published June 13th in the open-access journal PLoS Pathogens. Ecological globalization Ecosystems are constantly exchanging materials through the movement of air in the atmosphere, the flow of water in rivers and the migration of animals across the landscape. New strategies against bird flu The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS). Discovery could lead to better control of hemorrhagic fever viruses Researchers report discovering the receptor through which a group of life-threatening hemorrhagic fever viruses enter and attack the body's cells, and show that infection can be inhibited by blocking this receptor. Setting the Stage to Find Drugs Against SARS Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002. More SARS Virus Current Events and SARS Virus News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||